Stealth Biotherapeutics received FDA accelerated approval for its drug elamipretide (Forzinity) to improve muscle strength in patients with Barth syndrome, a rare pediatric mitochondrial disease. This approval follows previous regulatory hurdles including a response letter from the FDA. The development journey underscores challenges in rare disease drug approvals and represents an important treatment advancement for this ultra-rare genetic condition.